Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2016-03-03

Clinical Trial Update: Atorvastatin to Prevent Avascular Necrosis of Bone in Steroid Treated Exacerbated Systemic Lupus Erythematosus [Phase 2]

View source ↗

Summary

Phase 2 trial investigating atorvastatin to prevent avascular necrosis in steroid-treated patients with systemic lupus erythematosus was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • atorvastatin (atorvastatin)

Snippet

Sponsor: NYU Langone Health | Conditions: Avascular Necrosis | Phase 2 | Status: TERMINATED | Results posted: 2016-03-03